tert-Butyl 4-[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]piperazine-1-carboxylate

Catalog No. :
ACLNXE820
CAS No. :
745048-06-0
Molecular Formula :
C21H29N3O4
Molecular Weight :
387.48

IUPAC Name:tert-butyl 4-(4-(1,3-dioxoisoindolin-2-yl)butyl)piperazine-1-carboxylate

tert-Butyl 4-[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$178.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(4-(1,3-dioxoisoindolin-2-yl)butyl)piperazine-1-carboxylate
MDL No.MFCD19981496
Molecular FormulaC21H29N3O4
Molecular Weight387.48
SMILESO=C(N1CCN(CCCCN(C(C2=C3C=CC=C2)=O)C3=O)CC1)OC(C)(C)C
InChI KeyVHSSZNZSUPSTEJ-UHFFFAOYSA-N
Synonym4-[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-piperazine-1-carboxylic acid tert-butyl este;4-[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-piperazine-1-carboxylic acid tert-butyl ester;1-Piperazinecarboxylic acid, 4-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-, 1,1-dimethylethyl ester;Tert-butyl 4-(4-(1,3-dioxoisoindolin-2-yl)butyl)piperazine-1-carboxylate
CAS No.745048-06-0

Synthetic Route by SureRoute

1. ACLNXE820 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTBIW637 route compound structure diagram
    ACTBIW6375394-18-3 In Stock
  2. Then
  3. ACLNXE820 route product structure diagram
    ACLNXE820745048-06-0
Inquiry

2. ACLNXE820 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACTBIW637 route compound structure diagram
    ACTBIW6375394-18-3 In Stock
  4. Then
  5. ACLNXE820 route product structure diagram
    ACLNXE820745048-06-0
Inquiry

Comments (0)